# The Clorox Company (CLX)

> Source: Nexqual · https://nexqual.com/CLX · data as of 2026-10-22 20:00 UTC · cite as "Nexqual, The Clorox Company (CLX), nexqual.com/CLX" · informational, not investment advice.

**Price:** USD 88.66 (+4.59% on the day) · last close of Oct 22, 2026; US market pre market, not a live price. Prev close 84.77 · day 85.18–88.7 · 52w 79.12–128.9 · market cap $10.7B · NYQ

## Key facts
- Last four reported quarters (through Mar 31, 2026): revenue $6.76B, net income $756M (11.2% margin), free cash flow $380M (SEC filings).
- Valuation: P/E 14.2x (avg 70.6x at the last 3 fiscal year-ends), net debt $2.89B.
- 5 of 80 tracked superinvestors hold CLX (13F, Q2 2026): 0 new, 2 added, 2 reduced, 1 unchanged.
- Insider open-market purchases, last ~7 months: 1 Form 4 filing, $429K; 0 by opportunistic insiders, 0 by routine insiders.
- Analysts: Hold (mean 3.28 on a 1–5 scale) (18 analysts), mean target USD 96.35 (range 74–154).
- Total return with dividends: 1Y -21.1% vs S&P 500 +14.9%; 5Y -34.5% vs S&P 500 +80.3%.
- Next earnings: 2026-11-02, EPS estimate USD 1.07, revenue estimate $1.88B.

## Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $7.34B | $7.11B | $7.39B | $7.09B | $7.10B | $6.76B |
| Gross profit | $3.20B | $2.54B | $2.91B | $3.05B | $3.21B | — |
| Net income | $710M | $462M | $149M | $280M | $810M | $756M |
| EPS (diluted) | $5.58 | $3.73 | $1.20 | $2.25 | $6.52 | — |
| Free cash flow | $945M | $535M | $930M | $483M | $761M | $380M |
| Gross margin | 43.6% | 35.8% | 39.4% | 43.0% | 45.2% | — |
| Net margin | 9.7% | 6.5% | 2.0% | 3.9% | 11.4% | 11.2% |
| Revenue growth | +9.2% | -3.2% | +4.0% | -4.0% | +0.2% | — |
| Cash + short-term investments | $319M | $183M | $367M | $202M | $167M | — |
| Total debt | $2.78B | $2.47B | $2.48B | $2.48B | $2.48B | — |
Fiscal years end Jun. EPS is split-adjusted.

## Valuation (price ÷ last four quarters, through Mar 31, 2026)
P/E 14.2x · P/S 1.6x · EV/Sales 2.0x · P/FCF 28.2x · FCF yield 3.54% · Earnings yield 7.05% · Dividend yield (paid, TTM) 5.61% · Buyback yield (TTM) 3.09% · Net debt $2.89B · EV $13.6B
P/E at fiscal year-ends: Jun 2025 18.4x, Jun 2024 60.8x, Jun 2023 132.5x.

## Superinvestors (SEC 13F-HR, Q2 2026)
5 of 80 tracked investors hold CLX. Each row is the investor's latest 13F; change is vs their prior-quarter share count.
| Investor | Firm | % of portfolio | Value | Change |
|---|---|---|---|---|
| Hillman Capital | Hillman Capital Management | 0.24% | $337K | Reduced -0.7% |
| Terry Smith | Fundsmith | 0.19% | $25.9M | Added +5.5% |
| Jensen Investment Management |  | 0.11% | $4.6M | Added +3.5% |
| Yacktman Asset Management |  | 0.06% | $4.6M | Unchanged |
| Lee Ainslie | Maverick Capital | <0.01% | $349K | Reduced -77.8% |

## Insider purchases (SEC Form 4, open-market, last ~7 months)
1 purchase, $429K. Private placements, offerings, dividend reinvestment and employee stock purchase plan buys are excluded.
| Trade date | Insider | Role | Shares | Value | Avg price | Insider type |
|---|---|---|---|---|---|---|
| 2026-05-05 | Breber Pierre R | Director | 5,000 | $429K | 85.82 | Too little history (no open-market trades in 2023 or 2024) |
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.

## Analysts
Consensus Hold (mean 3.28 on a 1–5 scale), 18 analysts; mean target USD 96.35 (low 74, high 154).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-19 | JP Morgan | Target lowered | Underweight | $95 → $83 |
| 2026-10-16 | Barclays | Target lowered | Underweight | $84 → $80 |
| 2026-10-15 | Morgan Stanley | Target lowered | Equal-Weight | $97 → $87 |
| 2026-10-14 | Citigroup | Target lowered | Neutral | $97 → $90 |
| 2026-10-13 | TD Cowen | Target lowered | Hold | $85 → $80 |
| 2026-10-05 | Wells Fargo | Target lowered | Equal-Weight | $90 → $85 |
| 2026-09-11 | Citigroup | Target lowered | Neutral | $100 → $97 |
| 2026-09-11 | Wells Fargo | Target lowered | Equal-Weight | $102 → $90 |
| 2026-08-04 | UBS | Target raised | Neutral | $100 → $105 |
| 2026-08-04 | JP Morgan | Target raised | Underweight | $92 → $95 |
| 2026-08-04 | Citigroup | Target raised | Neutral | $97 → $100 |
| 2026-08-04 | Wells Fargo | Target raised | Equal-Weight | $95 → $102 |

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-23) | 5Y (from 2021-10-18) |
|---|---|---|
| Total return | -21.1% | -34.5% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | -21.1% | -8.1% |
| Volatility (annualized) | 32.1% | 27.9% |
| Max drawdown | -35.2% (Feb 2026→Oct 2026) | -49.0% (Jan 2022→Sep 2026) |

## Peers (Household & Personal Products)
ELF (e.l.f. Beauty, Inc.) USD 114.99 +1.06% · CHD (Church & Dwight Company, Inc.) USD 108.86 +3.68% · IPAR (Interparfums, Inc.) USD 116.07 +2.54% · KMB (Kimberly-Clark Corporation) USD 112.32 +5.32% · KVUE (Kenvue Inc.) USD 19.88 +4.41% · EL (Estee Lauder Companies, Inc. (T) USD 107.72 +3.92%

## More
Full page: https://nexqual.com/CLX · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt

## Supply chain and relationships (SEC annual reports)

Named in CLX's own 10-K filed 2026-08-07 (https://www.sec.gov/Archives/edgar/data/21076/000002107626000034/clx-20260630.htm):

| Relationship | Company | Sentence in the filing |
|---|---|---|
| Partner | Procter & Gamble (PG) | "The Company's venture agreement with The Procter & Gamble Company (P&G) for the Company's Glad bags and wraps business (the Venture Agreement) expired on January 31, 2026." |

## Revenue by business segment (quarter ended 2026-06-30)

| Line | Revenue | Share | YoY |
|---|---|---|---|
| Health and Wellness | $860.0M | 44.1% | +16.1% |
| Household | $524.0M | 26.9% | -18.0% |
| International | $281.0M | 14.4% | +4.5% |
| Lifestyle | $280.0M | 14.4% | -17.4% |
| Total revenue | $1.95B | 100% | — |

## Revenue by region (fiscal year ended 2026-06-30)

| Line | Revenue | Share | YoY |
|---|---|---|---|
| United States | $5.63B | 83.8% | -7.4% |
| Foreign | $1.09B | 16.2% | +6.5% |
| Total revenue | $6.72B | 100% | — |

## Customer concentration

Period ended 2026-06-30: 26% of revenue from unnamed direct customers (10-K, filed 2026-08-07).

## Company outlook (8-K filed 2026-08-03)

- "Delivers Q4 results in line with expectations while advancing strategic investments OAKLAND, California, Aug. 3, 2026 — The Clorox Company (NYSE: CLX) today reported results for the fourth quarter and fiscal year 2026, which ended June 30, 2026."
- "The impact of ERP-related shipment comparison was about 90 cents. "Our fourth-quarter results were in line with our expectations and reflect disciplined execution in a dynamic environment," said Chair and CEO Linda Rendle. "Throughout fiscal year 2026, we strengthened our business despite continued consumer and macroeconomic pressures."

## Analyst estimates and revisions

| Period | EPS est. | 90d ago | Change | Revenue est. | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends 2026-09-30) | $1.07 | $1.21 | -11.7% | $1.88B | 15 |
| Next quarter (ends 2026-12-31) | $1.34 | $1.39 | -3.6% | $1.89B | 15 |
| Current fiscal year (ends 2027-06-30) | $5.70 | $6.02 | -5.2% | $7.63B | 19 |
| Next fiscal year (ends 2028-06-30) | $6.13 | $6.54 | -6.2% | $7.82B | 18 |